Ocriplasmin
Also known as: Jetrea, Microplasmin, OTX-008, recombinant human plasmin, TSP-64
Source Ocriplasmin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Ocriplasmin (brand name Jetrea) is a recombinant protease administered via intravitreal injection to treat symptomatic vitreomacular adhesion and facilitate macular hole closure.
Mechanism of Action
Enzymatic cleavage of fibronectin and laminin at the vitreoretinal interface, inducing vitreolysis and release of vitreomacular adhesion.
Routes of Administration
Goals & Uses
- Macular hole closureOphthalmologyHigh
- Pharmacologic vitreolysisOphthalmic / VitreoretinalHigh
- Resolution of symptomatic vitreomacular adhesion (VMA)Ophthalmic / VitreoretinalHigh
- Vitreomacular adhesion releaseOphthalmologyHigh
- Non-surgical closure of macular holes ≤400 µmOphthalmic / VitreoretinalHigh
Contraindications
- Severe retinal detachmentRetinal PathologyHigh
- History of rhegmatogenous retinal detachmentOcular ConditionHigh
- Recent intraocular surgery (<30 days)Surgical HistoryModerate
- Known hypersensitivity to ocriplasmin or excipientsAllergyHigh
- Large macular holes (>400 µm)AnatomicalHigh
- Exudative age-related macular degenerationOcular ConditionModerate
- Active intraocular infectionOcular InfectionHigh
- Proliferative diabetic retinopathyOcular ConditionHigh
- High myopia (axial length >26 mm or refractive error > -8 diopters)Ocular ConditionModerate
Adverse Effects
- Transient decreased visual acuityOcularCommon
- Retinal detachmentOcularUncommon
- Cataract progressionLensRare
- Intraocular inflammation (uveitis)InflammatoryRare
- Dyschromatopsia (color vision changes)OcularUncommon
- Photopsia (flashes of light)OcularCommon
- Retinal tear or detachmentRetinalUncommon
- Transient visual lossVisualCommon
- Macular hole enlargementOcularUncommon
- Vitreous floatersOcularCommon
- Photopsia (flashing lights)VisualCommon
Drug Interactions
- Intravitreal anti‑VEGF agents (e.g., ranibizumab, aflibercept)Moderate
- Anti-VEGF agents (e.g., ranibizumab, bevacizumab)Low
- Intravitreal steroids (e.g., triamcinolone)Low
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patients (<18 years)AgeAbsolute
- Pediatric patientsAgeRelative
- Patients with lens zonule weaknessOcular ConditionRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: symptomatic vitreomacular adhesionEMA approval (2013) with restricted use; post‑marketing surveillance ongoing.
- United StatesApprovedApproved: symptomatic vitreomacular adhesionApproved by FDA (2012). Label includes boxed warning for vision loss.
- United KingdomApprovedApproved: symptomatic vitreomacular adhesionAvailable under NHS with specialist prescription.
FDA approved in 2012 (US) and EMA approved in 2013 (EU). Post‑marketing safety concerns have led to restricted labeling and limited use, but the drug remains approved.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Ocriplasmin?
Ocriplasmin (brand name Jetrea) is a recombinant protease administered via intravitreal injection to treat symptomatic vitreomacular adhesion and facilitate macular hole closure.
What is Ocriplasmin used for?
Ocriplasmin is educationally associated with: Macular hole closure, Pharmacologic vitreolysis, Resolution of symptomatic vitreomacular adhesion (VMA), Vitreomacular adhesion release, Non-surgical closure of macular holes ≤400 µm. Educational only — not medical advice.
How is Ocriplasmin administered?
Recorded routes of administration: Intravitreal.
What are the potential side effects of Ocriplasmin?
Reported adverse effects include: Transient decreased visual acuity, Retinal detachment, Cataract progression, Intraocular inflammation (uveitis), Dyschromatopsia (color vision changes), Photopsia (flashes of light), Retinal tear or detachment, Transient visual loss, Macular hole enlargement, Vitreous floaters, Photopsia (flashing lights). This list is not exhaustive — consult a qualified clinician.
Who should avoid Ocriplasmin?
Recorded contraindications: Severe retinal detachment, History of rhegmatogenous retinal detachment, Recent intraocular surgery (<30 days), Known hypersensitivity to ocriplasmin or excipients, Large macular holes (>400 µm), Exudative age-related macular degeneration, Active intraocular infection, Proliferative diabetic retinopathy, High myopia (axial length >26 mm or refractive error > -8 diopters). Consult a qualified clinician before use.